News

  • Acquisition Delivers AI and Data Engineering Expertise, Enterprise Analytics and Technology-Enabled Solutions to Accelerate Customer Performance MORRISVILLE, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization,
    10.06.21
  • Acquisition Offers Sites and Sponsors Access to Technology-Enabled, Insight-Powered Solutions, Accelerating Clinical Trial Recruitment, Retention and Diversity MORRISVILLE, N.C., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions
    09.14.21
  • Partnership Creates a More Patient-centric Travel Experience, Drives Adherence and Advances Diversity and Inclusion in Clinical Research MORRISVILLE, N.C. and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions
    09.09.21
  • MORRISVILLE, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present at the 2021 Baird
    08.30.21
  • Highlights Second quarter revenue of $1,282.6 million, increased 6.1% sequentially and 26.6% year-over-year. Clinical Solutions net new business awards of $1,436.2 million for the second quarter, representing year-over-year growth of 21.2% and a book-to-bill ratio of 1.45x, and $4,971.5 million for
    08.09.21
  • Partnership will enable biopharma companies to accelerate clinical development, market access, and the uptake of new therapies MORRISVILLE, N.C. and NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH) and Aetion ® announced a partnership to provide regulatory-grade data and
    08.02.21
  • Newly Created Role Demonstrates Company’s Commitment to Growth and Innovation as Industry Leader in Biopharmaceutical Product Development MORRISVILLE, N.C., July 14, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today
    07.14.21
  • MORRISVILLE, N.C., July 12, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to its earnings call at 8:00 a.m. ET.
    07.12.21
  • Newly Established Site Advocacy Group will Deliver Deeper, More Meaningful Site-Based Insights to Drive Adoption of Decentralized Clinical Trials Methodologies & Technologies MORRISVILLE, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated
    06.21.21
  • MORRISVILLE, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of David S. Wilkes, M.D., to the Company’s Board of Directors. “We are thrilled to welcome Dr.
    06.16.21
  • Consortium Advances Behavioral Insights and Diverse Patient Perspectives Across Product Development Lifecycle MORRISVILLE, N.C., June 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today launched its Patient Voice
    06.03.21
  • MORRISVILLE, N.C., June 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of
    06.03.21
  • MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten secondary offering by affiliates of Thomas H.
    06.02.21
  • MORRISVILLE, N.C., May 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences: Chief Executive Officer Alistair Macdonald is scheduled to
    05.21.21
  • Healthcare Businesswomen’s Association Shines a Light on Lynn Hamilton and Katya Magonova MORRISVILLE, N.C., May 06, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Lynn Hamilton, Senior Director,
    05.06.21
  • MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of
    05.03.21
  • MORRISVILLE, N.C. , May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten secondary offering by affiliates of Thomas H.
    05.03.21
  • Enterprise Partnership Enables Innovative Common Data Foundation Across Clinical, Real-World and Commercial Data by Combining Komodo Health’s Prism and Sentinel Solutions MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical
    05.03.21
  • MORRISVILLE, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- The Illingworth Research Group, a Syneos Health ® company, has been recognized with a 2021 Queen’s Award for Enterprise for International Trade. Illingworth Research Group™ is a leading global provider of clinical research home health services.
    04.30.21
  • Highlights Revenue of $1,208.7 million for the three months ended March 31, 2021, representing a sequential increase of 6.0% compared to the three months ended December 31, 2020, and a year-over-year increase of 3.9% compared to the three months ended March 31, 2020.
    04.29.21
  • New Partnership Leverages Medable’s Patient-Centered Cloud Platform, Accelerating Seamless Real-World Data Capture and Fit-for-Purpose Decentralized Solutions MORRISVILLE, N.C. and PALO ALTO, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated
    04.20.21
  • MORRISVILLE, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial results on Thursday, April 29, 2021, prior to its earnings call at 8:00 a.m. ET.
    04.01.21
  • Science 37’s Technology-First Operating System Further Powers Syneos Health’s Decentralized Solutions MORRISVILLE, N.C. and LOS ANGELES, March 29, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Science 37, the
    03.29.21
  • Senior Leaders Bring Decades of Creative, Brand and Strategy Experience MORRISVILLE, N.C., March 15, 2021 (GLOBE NEWSWIRE) -- Syneos Health Communications – the portfolio of Syneos Health ® agencies designed to deliver insights-driven integrated communications spanning advertising, public
    03.15.21
  • MORRISVILLE, N.C. , March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today
    03.01.21
  • MORRISVILLE, N.C. , March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today
    03.01.21
  • Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review MORRISVILLE, N.C. and SALT LAKE CITY , Feb. 24, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Protocol First, Inc.
    02.24.21
  • Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy MORRISVILLE, N.C. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Syneos Health Communications – the portfolio of Syneos Health ® agencies designed to deliver insights-driven integrated communications spanning advertising,
    02.23.21
  • Highlights GAAP revenue of $1,140.0 million for the three months ended December 31, 2020 , representing a sequential increase of 3.7% compared to the three months ended September 30, 2020 . Net new business awards of $1,764.1 million and $5,863.1 million for the three and twelve months ended
    02.18.21
  • Shared Commitment to Change, New Prescriber Realities, Model Evolution and Engagement Transformation Expected to be Critical Drivers MORRISVILLE, N.C. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, is pulsing a
    02.11.21
  • MORRISVILLE, N.C. , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2020 financial results on Thursday, February 18, 2021 , prior to its earnings call at 8:00 a.m. ET .
    01.26.21
  • MORRISVILLE, N.C. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that Chief Executive Officer
    01.04.21